Productive collaborations between biotech and major pharma provide a long-term competitive advantage and drive value when they move forward. Meanwhile, stalled collaborations drain resources from both organizations and fail to produce meaningful results for patients. So how do we create deals with the best potential to reap the most reward? Big pharma and biotech dealmakers will discuss what must be done to make their collaborations work while maintaining the best results - which deals are likely to pay dividends and which collaborations are usually avoided. An experienced dealmaker will moderate a lively discussion, while sharing some of her own tips and tricks for establishing and managing successful collaborations with prominent big pharma companies.